1.06Open1.06Pre Close0 Volume5 Open Interest12.50Strike Price0.00Turnover249.03%IV29.76%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry1.06Extrinsic Value100Contract SizeAmericanOptions Type0.4449Delta0.0799Gamma8.20Leverage Ratio-0.0759Theta0.0012Rho3.65Eff Leverage0.0078Vega
Alto Neuroscience Stock Discussion
Core business and technology:
Personalized Medication: Alto Neuroscience’s goa...
NEWS
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
ALTO-101 demonstrated favorable pharmacokinetic and tolerability profile in Phase 1 study
Transdermal formulation provided significantly greater drug exposure with fewer adverse events
Proof-of-concept study for CIAS to start in the first half of 2024
Topline data expected in the second half of 2025
Achievement of target exposure with propri...
No comment yet